14 research outputs found
A Poglut1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss
Skeletal muscle regeneration by muscle satellite cells is a physiological mechanism activated upon muscle damage and regulated by Notch signaling. In a family with autosomal recessive limbgirdle muscular dystrophy, we identified a missense mutation in
POGLUT1 (protein O-glucosyltransferase 1), an enzyme involved in Notch posttranslational modification and function. In vitro and in vivo experiments demonstrated that the mutation reduces Oglucosyltransferase activity on Notch and impairs muscle development. Muscles from patients revealed decreased Notch signaling,
dramatic reduction in satellite cell pool and a muscle-specific adystroglycan hypoglycosylation not present in patients’ fibroblasts. Primary myoblasts from patients showed slow proliferation, facilitated differentiation, and a decreased pool of quiescent PAX7+
cells. A robust rescue of the myogenesis was demonstrated by increasing Notch signaling. None of these alterations were found in muscles from secondary dystroglycanopathy patients. These data suggest that a key pathomechanism for this novel form of muscular dystrophy is Notch-dependent loss of satellite cells.Junta de Andalucía PI-0017-201
Altered myogenesis and premature senescence underlie human TRIM32-related myopathy
TRIM32 is a E3 ubiquitin -ligase containing RING, B-box, coiled-coil and six C-terminal NHL domains. Mutations
involving NHL and coiled-coil domains result in a pure myopathy (LGMD2H/STM) while the only described
mutation in the B-box domain is associated with a multisystemic disorder without myopathy (Bardet-Biedl
syndrome type11), suggesting that these domains are involved in distinct processes. Knock-out (T32KO) and knockin
mice carrying the c.1465G > A (p.D489N) involving the NHL domain (T32KI) show alterations in muscle regrowth
after atrophy and satellite cells senescence. Here, we present phenotypical description and functional
characterization of mutations in the RING, coiled-coil and NHL domains of TRIM32 causing a muscle dystrophy.
Reduced levels of TRIM32 protein was observed in all patient muscle studied, regardless of the type of mutation
(missense, single amino acid deletion, and frameshift) or the mutated domain. The affected patients presented with
variable phenotypes but predominantly proximal weakness. Two patients had symptoms of both muscular
dystrophy and Bardet-Biedl syndrome. The muscle magnetic resonance imaging (MRI) pattern is highly variable
among patients and families. Primary myoblast culture from these patients demonstrated common findings
consistent with reduced proliferation and differentiation, diminished satellite cell pool, accelerated senescence of
muscle, and signs of autophagy activation.Health Institute Carlos III PI16-01843 JR15/00042FEDER PI16-01843 JR15/00042Fundación Progreso y Salud, Junta de Andalucía PI-0085-2016Australian National Health and Medical Research Council (NHMRC) APP1122952 APP111751
Altered myogenesis and premature senescence underlie human TRIM32-related myopathy
TRIM32 is a E3 ubiquitin -ligase containing RING, B-box, coiled-coil and six C-terminal NHL domains. Mutations
involving NHL and coiled-coil domains result in a pure myopathy (LGMD2H/STM) while the only described
mutation in the B-box domain is associated with a multisystemic disorder without myopathy (Bardet-Biedl
syndrome type11), suggesting that these domains are involved in distinct processes. Knock-out (T32KO) and knockin
mice carrying the c.1465G > A (p.D489N) involving the NHL domain (T32KI) show alterations in muscle regrowth
after atrophy and satellite cells senescence. Here, we present phenotypical description and functional
characterization of mutations in the RING, coiled-coil and NHL domains of TRIM32 causing a muscle dystrophy.
Reduced levels of TRIM32 protein was observed in all patient muscle studied, regardless of the type of mutation
(missense, single amino acid deletion, and frameshift) or the mutated domain. The affected patients presented with
variable phenotypes but predominantly proximal weakness. Two patients had symptoms of both muscular
dystrophy and Bardet-Biedl syndrome. The muscle magnetic resonance imaging (MRI) pattern is highly variable
among patients and families. Primary myoblast culture from these patients demonstrated common findings
consistent with reduced proliferation and differentiation, diminished satellite cell pool, accelerated senescence of
muscle, and signs of autophagy activation.Health Institute Carlos III PI16-01843 JR15/00042FEDER PI16-01843 JR15/00042Fundación Progreso y Salud, Junta de Andalucía PI-0085-2016Australian National Health and Medical Research Council (NHMRC) APP1122952 APP111751
A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss
Skeletal muscle regeneration by muscle satellite cells is a physiological mechanism activated upon muscle damage and regulated by Notch signaling. In a family with autosomal recessive limb-girdle muscular dystrophy, we identified a missense mutation in 1 (protein O -glucosyltransferase 1), an enzyme involved in Notch posttranslational modification and function. In vitro and in vivo experiments demonstrated that the mutation reduces O -glucosyltransferase activity on Notch and impairs muscle development. Muscles from patients revealed decreased Notch signaling, dramatic reduction in satellite cell pool and a muscle-specific α-dystroglycan hypoglycosylation not present in patients' fibroblasts. Primary myoblasts from patients showed slow proliferation, facilitated differentiation, and a decreased pool of quiescent 7 + cells. A robust rescue of the myogenesis was demonstrated by increasing Notch signaling. None of these alterations were found in muscles from secondary dystroglycanopathy patients. These data suggest that a key pathomechanism for this novel form of muscular dystrophy is Notch-dependent loss of satellite cells
Presenilin/γ-Secretase Regulates Neurexin Processing at Synapses
Neurexins are a large family of neuronal plasma membrane proteins, which function as trans-synaptic receptors during synaptic differentiation. The binding of presynaptic neurexins to postsynaptic partners, such as neuroligins, has been proposed to participate in a signaling pathway that regulates synapse formation/stabilization. The identification of mutations in neurexin genes associated with autism and mental retardation suggests that dysfunction of neurexins may underlie synaptic defects associated with brain disorders. However, the mechanisms that regulate neurexin function at synapses are still unclear. Here, we show that neurexins are proteolytically processed by presenilins (PS), the catalytic components of the γ-secretase complex that mediates the intramembraneous cleavage of several type I membrane proteins. Inhibition of PS/γ-secretase by using pharmacological and genetic approaches induces a drastic accumulation of neurexin C-terminal fragments (CTFs) in cultured rat hippocampal neurons and mouse brain. Neurexin-CTFs accumulate mainly at the presynaptic terminals of PS conditional double knockout (PS cDKO) mice lacking both PS genes in glutamatergic neurons of the forebrain. The fact that loss of PS function enhances neurexin accumulation at glutamatergic terminals mediated by neuroligin-1 suggests that PS regulate the processing of neurexins at glutamatergic synapses. Interestingly, presenilin 1 (PS1) is recruited to glutamatergic terminals mediated by neuroligin-1, thus concentrating PS1 at terminals containing β-neurexins. Furthermore, familial Alzheimer's disease (FAD)-linked PS1 mutations differentially affect β-neurexin-1 processing. Expression of PS1 M146L and PS1 H163R mutants in PS−/− cells rescues the processing of β-neurexin-1, whereas PS1 C410Y and PS1 ΔE9 fail to rescue the processing defect. These results suggest that PS regulate the synaptic function and processing of neurexins at glutamatergic synapses, and that impaired neurexin processing by PS may play a role in FAD
Regulación de la función sináptica de neurexinas por presenilinas: Implicaciones en la enfermedad de alzheimer
Tesis descargada de TESEOLas neurexinas son proteínas de membrana sináptica con cientos de isoformas que participan en la formación o establecimiento de las sinapsis. La interacción de neurexinas presinápticas con sus receptores postsinápticos, como las neuroliguinas, media un mecanismo bidireccional de señalización que regula la función de las sinapsis. Se han identificado mutaciones en genes de neurexinas y neuroliguinas en pacientes con autismo, retraso mental y esquizofrenia, sugiriendo que defectos en el sistema de señalización de neurexinas y neuroliguinas podrían subyacer algunas sinaptopatías. Por otro lado, la enfermedad de Alzheimer es un trastorno neurodegenerativo que se caracteriza por déficit sináptico, pérdida progresiva de memoria y neurodegeneración. La mayoría de las formas familiares de la enfermedad de Alzheimer (FAD) son causadas por mutaciones en los genes de presenilinas (PS), subunidades catalíticas del complejo gamma-secretasa.
El objetivo de la presente Tesis consistió en indagar si la función de neurexinas está regulada por presenilinas (PS), el componente activo del complejo gamma-secretasa encargado de proteolizar proteínas de membrana. Mutaciones en PS son las responsables de la mayoría de los casos de FAD.
Hemos identificado un procesamiento secuencial de neurexinas por metaloproteasas y PS/gamma-secretasa. Tras un primer corte proteolítico en el dominio extracelular mediado por metaloproteasas se libera el ectodominio soluble y se generan los fragmentos C-terminales (CTFs) unidos a membrana. Estos CTFs son posteriormente procesados proteolíticamente por el complejo PS/gamma-secretasa, como muestra el hecho de que la inhibición de la actividad PS/gamma-secretasa induce la acumulación de los CTFs de neurexinas in vivo e in vitro. Posteriormente se demostró que PS se recluta junto con neurexinas a los terminales glutamatérgicos en formación mediados por neuroliguinas en cultivos de neuronas de hipocampo y que los CTFs de neurexinas se acumulan principalmente en las fracciones presinápticas de los ratones dobles knockout condicionales de PS (PS cDKO) que carecen de PS en neuronas glutamatégicas. Por tanto, el procesamiento proteolítico de las neurexinas por PS/gamma-secretasa podría ocurrir en las sinapsis glutamatérgicas. A continuación se demostró que el procesamiento de las neurexinas por metaloproteasas y PS/gamma-secretasa, está estimulado por despolarización a través de una ruta en la que están implicados los receptores de glutamato tipo NMDA y AMPA. Además, hemos observado que el bloqueo de la función de PS disminuye la liberación de neurotransmisores en sinapsis glutamatérgicas mediadas por neurexinas-neuroliguinas. La inhibición de PS afecta tanto a los niveles sinápticos de neurexinas como los de CASK, ligando sináptico de neurexinas. Por último, demostramos que mutaciones en PS asociadas con FAD afectan al procesamiento de neurexinas, sugiriendo que PS podría regular la función sináptica de neurexinas y que defectos en el procesamiento de neurexinas pueden contribuir a los déficits sinápticos y de memoria asociados a la enfermedad de Alzheimer
Presenilin/gamma-secretase regulates neurexin processing at synapses
Neurexins are a large family of neuronal plasma membrane proteins, which function as trans-synaptic receptors during synaptic differentiation. The binding of presynaptic neurexins to postsynaptic partners, such as neuroligins, has been proposed to participate in a signaling pathway that regulates synapse formation/stabilization. The identification of mutations in neurexin genes associated with autism and mental retardation suggests that dysfunction of neurexins may underlie synaptic defects associated with brain disorders. However, the mechanisms that regulate neurexin function at
synapses are still unclear. Here, we show that neurexins are proteolytically processed by presenilins (PS), the catalytic
components of the c-secretase complex that mediates the intramembraneous cleavage of several type I membrane proteins. Inhibition of PS/c-secretase by using pharmacological and genetic approaches induces a drastic accumulation of neurexin C-terminal fragments (CTFs) in cultured rat hippocampal neurons and mouse brain. Neurexin-CTFs accumulate mainly at the presynaptic terminals of PS conditional double knockout (PS cDKO) mice lacking both PS genes in glutamatergic neurons of the forebrain. The fact that loss of PS function enhances neurexin accumulation at glutamatergic
terminals mediated by neuroligin-1 suggests that PS regulate the processing of neurexins at glutamatergic synapses.
Interestingly, presenilin 1 (PS1) is recruited to glutamatergic terminals mediated by neuroligin-1, thus concentrating PS1 at terminals containing b-neurexins. Furthermore, familial Alzheimer’s disease (FAD)-linked PS1 mutations differentially affect b-neurexin-1 processing. Expression of PS1 M146L and PS1 H163R mutants in PS2/2 cells rescues the processing of bneurexin-1, whereas PS1 C410Y and PS1 DE9 fail to rescue the processing defect. These results suggest that PS regulate the synaptic function and processing of neurexins at glutamatergic synapses, and that impaired neurexin processing by PS may play a role in FAD
Presenilin/Ɣ-secretase regulates neurexin processing at synapses
Neurexins are a large family of neuronal plasma membrane proteins, which function as trans-synaptic receptors during synaptic differentiation. The binding of presynaptic neurexins to postsynaptic partners, such as neuroligins, has been proposed to participate in a signaling pathway that regulates synapse formation/stabilization. The identification of mutations in neurexin genes associated with autism and mental retardation suggests that dysfunction of neurexins may underlie synaptic defects associated with brain disorders. However, the mechanisms that regulate neurexin function at synapses are still unclear. Here, we show that neurexins are proteolytically processed by presenilins (PS), the catalytic components of the Ɣ-secretase complex that mediates the intramembraneous cleavage of several type I membrane proteins. Inhibition of PS/Ɣ-secretase by using pharmacological and genetic approaches induces a drastic accumulation of neurexin C-terminal fragments (CTFs) in cultured rat hippocampal neurons and mouse brain. Neurexin-CTFs accumulate mainly at the presynaptic terminals of PS conditional double knockout (PS cDKO) mice lacking both PS genes in glutamatergic neurons of the forebrain. The fact that loss of PS function enhances neurexin accumulation at glutamatergic terminals mediated by neuroligin-1 suggests that PS regulate the processing of neurexins at glutamatergic synapses. Interestingly, presenilin 1 (PS1) is recruited to glutamatergic terminals mediated by neuroligin-1, thus concentrating PS1 at terminals containing β-neurexins. Furthermore, familial Alzheimer's disease (FAD)-linked PS1 mutations differentially affect β-neurexin-1 processing. Expression of PS1 M146L and PS1 H163R mutants in PS2/2 cells rescues the processing of β-neurexin-1, whereas PS1 C410Y and PS1 ∆E9 fail to rescue the processing defect. These results suggest that PS regulate the synaptic function and processing of neurexins at glutamatergic synapses, and that impaired neurexin processing by PS may play a role in FAD
Generation of an induced pluripotent stem cell line (CSCRMi001-A) from a patient with a new type of limb-girdle muscular dystrophy (LGMD) due to a missense mutation in POGLUT1 (Rumi)
Recently, a new type of limb-girdle muscular dystrophy (LGMD type 2Z) has been identified due to a missense mutation in POGLUT1 (protein O-glucosyltransferase-Rumi), an enzyme capable of adding glucose to a distinct serine residue of epidermal growth factor-like repeats containing a C-X-S-X-(P/A)-C consensus sequence such as Notch receptors. Affected patients demonstrate reduced Notch signaling, decreased muscle stem cell pool and hypoglycosylation of α-dystroglycan, leading to LGMD phenotype. Here we report the generation and characterization of an iPSC line (CSCRMi001-A) from a LGMD-2Z patient with missense mutation in POGLUT1 which can be used for in vitro disease modeling